search

Active clinical trials for "Bacteremia"

Results 71-80 of 283

Safety and Behavior of S. Aureus Immune Globulin Intravenous(Human), [Altastaph] in Patients With...

Staphylococcal Infections

Altastaph has been developed to help the removal of S. aureus from the bloodstream. The main objective of this study will be to test the safety and behavior of Altastaph in patients with S.aureus bacteremia and continuing fever

Completed16 enrollment criteria

Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia

Gram-Positive Bacterial Infections

The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be safety administered to patients with bloodstream infections and whether telavancin is effective in treating these infections.

Completed2 enrollment criteria

Duration of Antibiotics for the Treatment of Gram-negative Bacilli Bacteremia

Gram Negative Bacteremia

The investigators plan an open label randomized controlled trial to compare short-course antibiotic therapy (<=7 days) versus longer treatment (>7 days). The investigators will include hospitalized patients with gram-negative bacteremia. The investigators primary objective is to investigate the safety and efficacy of short-course antibiotics.

Completed31 enrollment criteria

Efficacy of Daptomycin Plus Fosfomycin Versus Daptomycin for Treatment of MRSA Bacteremia

Staph Aureus Methicillin Resistant Bacteremia

To demonstrate that the combination of daptomycin and fosfomycin is superior to daptomycin alone in the treatment of methicillin resistant Staphylococcus aureus (MRSA) bacteremia.

Completed12 enrollment criteria

Safety Evaluation of Seraph® 100 to Reduce Bacteremia in Patients on Hemodialysis

BacteremiaBacterial Infection

The purpose of this study is to determine whether the Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) is safe in the treatment of dialysis patients with bacteremia.

Completed32 enrollment criteria

Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants...

Bacteremia

This is a Phase Ib, randomized double-blind, placebo-controlled multiple-ascending dose study to investigate the safety, tolerability, and pharmacokinetics of multiple doses of DSTA4637S when given in addition to anti-staphylococcal SOC antibiotics to participants with methicillin-resistant staphylococcus aureus (MRSA) and methicillin-sensitive staphylococcus aureus (MSSA) bacteremia requiring at least 4 weeks of anti-staphylococcal SOC antibiotics.

Completed15 enrollment criteria

Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection

Bacteremia

The purpose of this study is to accurately determine the length of appropriate drug treatment for staphylococcal blood stream infection. The study seeks to address important information about the management of staphylococcal blood stream infections.

Completed34 enrollment criteria

Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream...

InfectionBacteremia

The goal of this clinical research study is to learn if Vibativ (telavancin) can help to control blood stream infections (BSIs). The safety of this treatment will also be studied. Objectives: Evaluate the clinical efficacy and safety of Telavancin given for treatment of gram positive bacteremia in cancer patients (including neutropenics).

Completed12 enrollment criteria

Efficacy, Immunogenicity, and Safety of a Single Dose of V710 in Adult Patients Scheduled for Cardiothoracic...

Staphylococcus AureusBacteremia1 more

This study will assess the efficacy of a single dose of V710 vaccine to prevent serious Staphylococcus aureus infections following elective cardiothoracic surgery. The study will also evaluate the immune response and general safety of the V710 vaccine.

Terminated11 enrollment criteria

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive...

Mycobacterium Avium-intracellulare InfectionHIV Infections

Primary: To provide rifabutin to HIV positive patients in an attempt to prevent or delay Mycobacterium avium Complex (MAC) infection by a daily dose of rifabutin. Secondary: To further characterize the safety of rifabutin monotherapy in preventing or delaying MAC bacteremia in HIV positive patients with CD4 counts = or < 200.

Completed19 enrollment criteria
1...789...29

Need Help? Contact our team!


We'll reach out to this number within 24 hrs